The 20 most recent market catalysts affecting $SPRO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Bullish
Impact 55
Safe Pro Group's SpotlightAI™ Wins "Scalable Innovation" Award
Safe Pro Group's SpotlightAI™ winning the 'Scalable Innovation' award is a positive development for the company. This recognition, from a global competition funded by the European …
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 92
Safe Pro Group Reports Record Third Quarter 2026 Financial Results
Safe Pro Group reported record third-quarter 2026 financial results, with revenue exceeding preliminary estimates and a significant contribution from its AI segment. The substantia…
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 85
Spero Therapeutics Announces Third Quarter 2026 Financial Results
Spero Therapeutics announced a net loss of $44.3 million for Q3 2026, a substantial increase from $7.4 million in Q3 2025. This wider loss was largely driven by a $35 million upfro…
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 55
Safe Pro Group Awarded Contract by Ukrainian Deminers Association
Safe Pro Group Inc. announced a contract win with the Ukrainian Deminers Association, operating under a UNMAS program, to supply American AI technology for demining in Ukraine. Thi…
Nov 11, 2026
Corporate Catalyst
Neutral
Impact 55
Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors
Spero Therapeutics announced the appointment of Dr. William Ho to its Board of Directors and Development Committee, effective November 10, 2026. This appointment fills a vacancy le…
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 75
Safe Pro Group Awarded U.S. Army Prime Contract for Ghost-X Drone Tank Protection
Safe Pro Group Inc. announced it has been awarded a prime contract by the U.S. Army. This contract involves a collaboration with Anduril Industries to integrate 'super intelligence…
Nov 6, 2026
Corporate Catalyst
Neutral
Impact 55
Alphabet Inc. Liquidates Share Stake in Spero Therapeutics
Alphabet Inc. (GOOGL) has liquidated its entire share stake in Spero Therapeutics (SPRO), signaling a complete exit from its investment in the biopharmaceutical company. This event…
Oct 28, 2026
Corporate Catalyst
Neutral
Impact 65
Spero Therapeutics Price Target Announced at $6.00/Share by Cantor Fitzgerald
Cantor Fitzgerald has initiated coverage of Spero Therapeutics, Inc. (SPRO) with an 'Overweight' rating and a $6.00 price target. This event is significant for SPRO as it introduce…
Oct 26, 2026
Corporate Catalyst
Neutral
Impact 55
Spero Therapeutics Announces Leadership Appointments and COO Retirement
Spero Therapeutics is making strategic leadership changes by appointing a Chief Regulatory and Quality Officer and a Senior Vice President, Corporate Development. These roles are c…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 85
Safe Pro Group Reports Preliminary Q3 Sales Of $2.5M+, Up 2,300%+ YoY, Driven By Multiple U.S. Government Subcontract Awards Supporting U.S. Army And Air Force
Safe Pro Group's 8-K filing reveals preliminary Q3 2026 revenue exceeding $2.5 million, a massive 2,300%+ increase year-over-year, and nine-month revenue over $5 million, up 1,200%…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6
HC Wainwright & Co. analyst Raghuram Selvaraju maintained a 'Buy' rating on Spero Therapeutics and raised the price target from $5 to $6. This indicates a continued positive view f…
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 55
Spero Therapeutics Files Prospectus To Offer Up To $300M In Securities
Spero Therapeutics filed a prospectus to offer up to $300 million in securities, which is a standard procedure for companies looking to raise capital. This filing itself does not m…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 65
Spero Therapeutics Q2 EPS $(0.16) Down From $(0.03) YoY
This headline directly impacts Spero Therapeutics (SPRO) as it reports a substantial year-over-year decline in EPS, moving further into negative territory. This indicates a worseni…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Safe Pro Group Enters Into Cooperative Research And Development Agreement For Unified Situational Intelligence With U.S. Army Engineer Research And Development Center
This Cooperative Research and Development Agreement (CRADA) is a positive development for Safe Pro Group (SPRO), indicating a potential expansion of its defense contracts and techn…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 65
Safe Pro Group Says 2026 AI-Related Orders Surpass $5M In Aggregate Contract Value Across 8 Contracts, Including New Government Subcontracts Received In August
This headline is a positive corporate catalyst for Safe Pro Group, indicating strong demand for their AI-related services, particularly within the government sector. The $5M aggreg…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Safe Pro Group shares are trading higher after the company announced a purchase order from a Department of War contractor for a package including its edge-based, AI-powered threat detection technologies and multiple Blue UAS drones.
This headline is a significant positive catalyst for Safe Pro Group, as it secures a major government contract, validating its technology and opening doors for future growth. The '…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Safe Pro Group Announces $780K Purchase Order From New Department Of War Prime Contractor For AI Threat Detection Tech, Blue UAS Drones
The $780K purchase order for Safe Pro Group (SPRO) is a positive corporate catalyst, demonstrating new business and a strategic entry into a significant defense supply chain. While…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 75
Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare Royalty
Spero Therapeutics secured a crucial $105 million non-recourse, non-dilutive royalty financing from KKR. This deal is highly significant as it provides substantial capital for the …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 75
Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China
Spero Therapeutics has entered a significant licensing agreement with Innovent Biologics, gaining exclusive global rights (excluding Greater China) to SP001. This deal involves an …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.